AtriCure Inc (ATRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AtriCure Inc (ATRC) has a cash flow conversion efficiency ratio of -0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.00 Million) by net assets ($491.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can AtriCure Inc fund operations to measure how many days the company can operate on defensive assets alone.
AtriCure Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how AtriCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AtriCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AtriCure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aura Investments Ltd
TA:AURA
|
-0.169x |
|
Trident Limited
NSE:TRIDENT
|
0.140x |
|
TripAdvisor Inc
NASDAQ:TRIP
|
0.189x |
|
Chengdu Spaceon Electronics Co Ltd Class A
SHE:002935
|
-0.067x |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
0.066x |
|
Jinhui Liquor Co Ltd
SHG:603919
|
-0.011x |
|
Shenzhen Desay Battery Technology Co Ltd
SHE:000049
|
0.015x |
|
Cardinal Energy Ltd
TO:CJ
|
0.049x |
Annual Cash Flow Conversion Efficiency for AtriCure Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of AtriCure Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see AtriCure Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $491.94 Million | $57.33 Million | 0.117x | +340.22% |
| 2024-12-31 | $460.97 Million | $12.20 Million | 0.026x | +175.24% |
| 2023-12-31 | $466.17 Million | $4.48 Million | 0.010x | +119.84% |
| 2022-12-31 | $456.75 Million | $-22.14 Million | -0.048x | -70.17% |
| 2021-12-31 | $483.76 Million | $-13.78 Million | -0.028x | +40.88% |
| 2020-12-31 | $412.39 Million | $-19.87 Million | -0.048x | +24.63% |
| 2019-12-31 | $247.34 Million | $-15.81 Million | -0.064x | -282.19% |
| 2018-12-31 | $249.38 Million | $-4.17 Million | -0.017x | +69.86% |
| 2017-12-31 | $161.17 Million | $-8.94 Million | -0.055x | +38.17% |
| 2016-12-31 | $168.44 Million | $-15.12 Million | -0.090x | -113.68% |
| 2015-12-31 | $186.69 Million | $-7.84 Million | -0.042x | +74.22% |
| 2014-12-31 | $132.54 Million | $-21.60 Million | -0.163x | -126.59% |
| 2013-12-31 | $72.60 Million | $-5.22 Million | -0.072x | +53.56% |
| 2012-12-31 | $12.50 Million | $-1.94 Million | -0.155x | -21.75% |
| 2011-12-31 | $15.61 Million | $-1.99 Million | -0.127x | -6267.96% |
| 2010-12-31 | $16.74 Million | $-33.43K | -0.002x | -108.13% |
| 2009-12-31 | $17.09 Million | $419.95K | 0.025x | +112.53% |
| 2008-12-31 | $29.12 Million | $-5.71 Million | -0.196x | +12.45% |
| 2007-12-31 | $36.24 Million | $-8.12 Million | -0.224x | +44.85% |
| 2006-12-31 | $30.69 Million | $-12.47 Million | -0.406x | -130.28% |
| 2005-12-31 | $43.18 Million | $-7.62 Million | -0.176x | -226.84% |
| 2004-12-31 | $-27.33 Million | $-3.80 Million | 0.139x | -- |
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; m… Read more